European Journal of Rheumatology
Original Article

Coronavirus Disease 2019 Outcomes in Amyloid A Protein Amyloidosis Secondary to Rheumatic Conditions and Signs of Post- Coronavirus Disease 2019 Proteinuria Progression


Department of Rheumatology, Ankara Bilkent City Hospital, Ankara, Turkey


Division of Rheumatology, Department of Internal Medicine, Gazi University, Medical School, Ankara, Turkey


Department of Emergency Medicine, Sincan Dr. Nafiz Körez State Hospital, Ankara, Turkey


Division of Rheumatology, Department of Internal Medicine,Yıldırım Beyazıt University, Medical School, Ankara, Turkey


Department of Rheumatology,Health Sciences University Medical School, Ankara Bilkent City Hospital, Ankara, Turkey

Eur J Rheumatol 1; 1: -
DOI: 10.5152/eurjrheum.2024.23050
Read: 120 Downloads: 95 Published: 04 April 2024

Background: We aimed to investigate coronavirus diease 2019 (COVID-19) outcomes in patients with amyloid A protein (AA) amyloidosis secondary to rheumatic diseases and discuss factors associated with disease course.

Methods: A retrospective cohort was formed from adult patients with a diagnosis of AA amyloidosis. In patients with a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR) test, rates of hospitalization, intensive care unit admission and mortality due to COVID-19 were collected from medical records. Data regarding to demographics, comorbidities, laboratory tests, medical treatments, adherence to previous treatments during COVID-19 and treatment administered for COVID-19 were collected from hospital databases and patient reviews.

Results: In 96 patients with AA amyloidosis, 16 had COVID-19 with a positive PCR. Ten (62.5%) patients were hospitalized, 2 (12.5%) were admitted to ICU, 1 (6.25%) was died. Hospitalized patients tended to be older. Comorbidities seemed to be more frequent in hospitalized patients. None of the patients had rapid progression to end-stage renal disease post-COVID-19. Seven patients had pre-COVID-19 and post-COVID-19 proteinuria levels. Three had notable increase in proteinuria after COVID-19 in 2 of which amyloidosis treatment was revised accordingly.

Conclusion: Despite high rates of hospitalization in AA amyloidosis patients, mortality was observed only in 1 patient. Progression of proteinuria requiring treatment adjustment may be an issue in these patients.

Cite this article as: Güven SC, Erden A, Küçük H, et al. Coronavirus disease 2019 outcomes in amyloid A protein amyloidosis secondary to rheumatic conditions and signs of post-coronavirus disease 2019 proteinuria progression. Eur J Rheumatol. Published online April 4, 2024. DOI:10.5152/eurjrheum.2024.23050

EISSN 2148-4279